Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Integrin alpha4, also known as CD49d, is a transmembrane protein that functions as an integrin alpha subunit. It forms heterodimers with either the beta1 (CD29) or beta7 integrin subunits to create functional receptors on the cell surface. The most notable complexes are: α4β1 (VLA-4) and α4β7 (LPAM-1). Integrins containing the alpha 4 subunit play critical roles in cell adhesion, cell-cell adhesion, and trafficking of hematopoietic cells. Antagonists targeting integrin alpha 4 have been developed for inflammatory diseases such as ulcerative colitis.
Antagonist targeting integrin alpha 4
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Integrin alpha4 (CD49d).